Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Eur Cell Mater. 2021 Sep 22;42:156–165. doi: 10.22203/eCM.v042a12

Fig. 2. Initial screen of serum anti-Gmd IgG4 vs. total anti-Gmd IgG levels in S. aureus bone infection patients with high levels against Gmd.

Fig. 2.

AO Trauma CPP Bone Infection Registry serum samples from patients with high anti-Gmd IgG levels (> 10 μg/mL) obtained at the time of their surgery for culture confirmed S. aureus bone infection (baseline) were divided into 2 groups: infection controlled at 1-year post-operation (IC, n = 12), and adverse outcome within 1 year (AD, n = 2, 1 knee fusion and 1 wound breakdown). The sera were analysed for IgG antibodies specific for Gmd using a Luminex™ to determine: (left) total IgG MFI, (centre) MFI for IgG4 specific antibodies, and (right) IgG4 MFI divided by total IgG MFI (RATIO). The data are presented for each patient with the median for the group without statistical analysis due to the small sample size.